Kornimate/medical-research-clean huggingface dataset:
music vs relaxation training in craving reduction in alcohol dependence syndrome

Conditions: Alcohol Dependence Syndrome

Summary: the aim of the study was to compare the effectiveness of music and progressive muscle relaxation as interventions to reduce craving, increase coping, and understand the subjective experience of the interventions with patients diagnosed with mental and behavioral disorders due to alcohol, dependence syndrome, over a 5 day period.

craving for alcohol produces an aversive, uncomfortable state, with autonomic arousal similar to that in anxiety disorders, and is the main factor leading to relapse. music has been shown to reduce anxiety and stress levels. progressive muscle relaxation (pmr) is the intervention of choice for treatment of anxiety and related syndromes. this study aimed to compare efficacy of pmr and music in reducing levels of alcohol craving and increasing perceived ability to cope with the craving. the intervention was conducted over 5 days with two randomised group of 10 patients each. the patients were assigned to either group based on randomizer sequencing. initial motivation was assessed before beginning the study. measures of craving level and coping were collected on day 1, 3 and 5. single question exit interview was conducted to understand subjective perception of the patients regarding the techniques. significant difference was found in coping levels through use of pmr (p = 0.01), and subjective reduction in craving levels was reported by patients in the music group, though this was not statistically significant. thus, pmr may be used as an adjunct to increase coping abilities in patients with alcohol dependence, while music may be a useful tool to reduce craving but cannot be conclusively commented upon without further research.

Eligibility criteria:
inclusion criteria: * diagnosed with mental and behavioral disorders due to use of alcohol, dependence syndrome * abstinent for at least 1 week exclusion criteria: * any other known psychiatric/physical condition * risk of suicide or relapse * less than 75% compliance
timing of preload responsiveness in sepsis

Conditions: Septic Shock; Fluid Responsiveness

Summary: during acute circulatory failure, volume expansion does not always lead to a significant increase in cardiac output (fluid responsiveness). after initial resuscitation by rapid fluid administration, cardiac preload is no longer extremely low and only half of the patients respond to further volume expansion with the expected increase in cardiac output (fluid unresponsiveness). however, the time delay or the volume of fluid needed to be administered from the state of fluid responsiveness to fluid unresponsiveness is still not determined. objective to determine, in critically ill patients with acute circulatory failure, 1. : the time and/or the volume of fluid needed from the state of fluid responsiveness to fluid unresponsiveness during septic shock. 2. : determine the factors that influence this time and volume.


Eligibility criteria:
inclusion criteria: * age ≥ 18 ans * onset of septic shock exclusion criteria: * planned to transfer the patient to another healthcare facility (inability to continue cardiac output measurements); urgent operation; inability to measure the cardiac output.
citrate anticoagulation during mars treatment

Conditions: Liver Failure

Summary: the optimal anticoagulation procedure during mars treatment has not been defined. in various multi-centre trials, such as mars-relief, anticoagulation procedures are left to the discretion of the treating physician. on the one hand, given the increased risk of bleeding associated with liver failure, high dosage of anticoagulation therapy should be avoided. on the other hand, contact of blood or blood components with the extracorporeal circuit will likely result in coagulation activation or even loss of coagulation factors. citrate anticoagulation has gained popularity, especially in hemodialysis patients. it results in a highly effective anticoagulation, exclusively confined to the extracorporeal circulation. moreover, dependent on the type of dialyser membrane, citrate anticoagulation resulted in reduced activation of other cellular components. in contrast to hemodialysis patients, experience with citrate anticoagulation during treatment with artificial liver devices is limited. the liver contributes substantially to the metabolism of exogenous citrate. as a result, cirrhotic patients have decreased endogenous citrate clearances. importantly, blood purification devices contribute substantially to overall citrate clearance, thereby preventing accumulation of citrate. several centres, including our own, have gained experience with citrate anticoagulation during fractionated plasma separation and adsorption (fpsa), a related liver dialysis device, in the treatment of liver failure patients. citrate anticoagulation during mars treatment has not been studied so far.


Eligibility criteria:
inclusion criteria: * scheduled mars treatment * age over 18 years * informed consent * admitted to intensive care unit exclusion criteria: * blood or plasma transfusion within 48 hours before study * hypocalcemia (ionised ca \< 0.90 mmol/l) * acidosis (ph \< 7.25) due to any cause * use of citrate containing medications

Keywords: mars treatment citrate anticoagulation
cognitive outcome after srs or wbrt in patients with multiple brain metastases (car-study b)

Conditions: Neoplasm Metastasis

Summary: whole brain radiation therapy (wbrt) has long been the mainstay of treatment for patients with multiple brain metastases (bm). meanwhile, gamma knife radiosurgery (gkrs) has been increasingly employed in the management of multiple bm to spare healthy tissue. hence, gkrs is expected to cause fewer cognitive side effects than wbrt. treatment of multiple bm without cognitive side effects is becoming more important, as more patients live longer due to better systemic treatment options. there are no published randomized trials yet directly comparing gkrs to wbrt in patients with multiple bm, including objective neuropsychological testing. car-study b is a prospective randomized trial comparing cognitive outcome after gkrs or wbrt in eligible patients with 11-20 bm.

car-study b is a prospective randomized trial comparing cognitive outcome after gkrs or wbrt in eligible patients with 11-20 bm on a triple dose gadolinium-enhanced mri-scan. neuropsychological assessment will be performed at baseline and at 3, 6, 9, 12 and 15 months after treatment. follow-up assessments will be combined with 3-monthly mri-scans. patients will be randomized to either gkrs or wbrt. groups will be balanced at baseline (prior to radiotherapy), taking into account several (stratification) factors that may influence cognitive functioning over time, such as: total tumor volume in the brain, systemic treatment, kps, age, histology, and baseline hvlt-r total recall score.

Eligibility criteria:
inclusion criteria: * histologically proven malignant cancer * 11-20 newly diagnosed brain metastases on a triple dose gadolinium-enhanced mri-scan * maximum total tumor volume ≤ 30 cm3 * lesion ≥ 3 mm from the optic apparatus * age ≥ 18 years * karnofsky performance status (kps) ≥ 70 * anticipated survival \> 3 months exclusion criteria: * no prior histologic confirmation of malignancy * primary brain tumor * a second active primary tumor * small cell lung cancer (sclc) * lymphoma * leukemia * meningeal disease * progressive, symptomatic systemic disease without further treatment options * prior brain radiation * prior surgical resection of bm * cardiovascular accident (cva) \< 2 years ago * additional history of a significant neurological or psychiatric disorder * contra indications to mri or gadolinium contrast * underlying medical condition precluding adequate follow-up * participation in a concurrent study in which neuropsychological testing and/or health-related qol assessments are involved * lack of basic proficiency in dutch * iq below 85 * severe aphasia * paralysis grade 0-3 according to mrc scale (medical research council)

Keywords: brain metastases cognition radiosurgery gamma knife radiosurgery stereotactic radiosurgery whole brain radiation therapy quality of life fatigue anxiety depression
comparison between pecs block 2 vs esp block in ocnologic breast surgery

Conditions: Breast Cancer; Breast Neoplasms; Breast Carcinoma

Summary: the study aims to compare the efficacy of the two operating blocks pecs2 and esp by measuring postoperative opioid consumption and, secondarily, to compare (between pecs and esp) postoperative opioid consumption between surgery with/without axillary cavity dissection and with/without implantation of prosthesis or expansion

breast cancer is the most frequent type of cancer in the female population. early detection is the most effective tool for improving prognosis, and the surgical approach plays a central role in the treatment of this disease. however, many are the psychophysical implications that patients face: among the main ones is postoperative and chronic pain, a symptom that greatly worsens the quality of life. in the last decade it has been witnessed an important development of locoregional anesthesia techniques in all surgeries. in breast surgery, particularly mastectomy, the following locoregional anesthesia techniques are referred to as the gold standard: 1. pvb (paravertebral block) 2. pecs2 block (or modified pecs). for the same purposes, esp block (erector spinae plane block) has been applied experimentally, which has already shown its effectiveness in breast surgery in several trials. by comparing postoperative opioid consumption between the two groups of patients, divided into pecs block and esp block, the study aims to identify which anesthesia block is most effective in order to improve the care of patients undergoing mastectomy.

Eligibility criteria:
inclusion criteria: * patients undergoing mastectomy exclusively for breast cancer * presence of written informed consent to the trial exclusion criteria: * bilateral breast surgery * previous drug use * chronic opioid and minor opioid therapy * bmi \>40 * allergy or contraindications to taking paracetamol and toradol * inability to use pca (patient controlled analgesia) * intraoperative opioid administration * patients with neuropathy

Keywords: pecs2 esp block breast anesthesia mastectomy breast cancer
study of gemcitabine and vinorelbine in soft tissue sarcomas

Conditions: Sarcoma, Soft Tissue

Summary: the purpose of this study is to determine if the combination of gemcitabine and vinorelbine is effective in treating patients with advanced soft tissue sarcoma.

patients will receive both gemcitabine and vinorelbine once a week for two weeks and then one week with no chemotherapy (1 cycle equals 21 days). gemcitabine and vinorelbine will be administered on day 1 and day 8 of each cycle. blood tests will be performed on each day chemotherapy is administered. a ct scan will be done after every 2 cycles (approximately every 6 weeks) to determine the effects of the chemotherapy on the sarcoma. a physical exam will be performed at the start of chemotherapy and at least every three weeks thereafter. patients will remain on this study as long as the disease does not progress or there are no unacceptable side effects.

Eligibility criteria:
inclusion criteria: * histologic diagnosis of unresectable or metastatic soft tissue sarcoma * measurable disease outside of a prior irradiated area * ecog performance status 0,1, or 2. * 0 or 1 prior regimens for advanced disease. * adequate end organ function, defined as bilirubin \< 1.8; sgot/sgpt \< 2.5 x upper limit of normal (uln); creatinine \< 1.5 x uln. * negative pregnancy test * life expectancy of greater than 3 months exclusion criteria: * patient has received any investigational agents within 28 days of first day of study drug dosing * two or more prior regimens for advanced disease * prior gemcitabine or vinorelbine * another primary malignancy * grade iii/iv cardia dysfunction * female patients who are pregnant or breast-feeding * severe and/or life-threatening medical disease * known diagnosis of hiv infection * prior chemotherapy within 4 weeks prior to study entry * major surgery within 2 weeks prior to study entry * known hypersensitivity to either gemcitabine or vinorelbine

Keywords: soft tissue sarcoma metastatic soft tissue sarcoma gemcitabine vinorelbine
a comparative study of the effect of two partographs on the cesarean section rate in women in spontaneous labour

Conditions: Dystocia

Summary: in the 2010-french perinatal survey, the overall cesarean section (cs) rate during labour was 21 % and 16% to 38% in case of dystocia. the definition of " dystocia " is traditionally based on the research led by friedman in the 1950's on a restricted population sample. several studies over the last years seem to indicate that the different phases of labour are longer than originally described by friedman. our current hypothesis is that the application of a new definition of dystocia would enable a more appropriate management of labour.

the main purpose of this study is to show a significant decrease of the cs rate with the use of the new partograph developed by neal and lowe. secondary purposes are * to reduce the use of oxytocin during labour without increasing maternal or neonatal morbidity; * to decrease immediate per-operative complications and post-operative complications associated with cs

Eligibility criteria:
inclusion criteria: age ≥ 18 years * affiliation to a social security insurance * written consent given * singleton pregnancy * cephalic presentation * ≥37 gestational weeks * spontaneous onset of labour exclusion criteria: * previous cesarean section * induction of labour * intrauterine growth restriction * in utero fetal death * congenital malformation * chorioamnionitis * placenta praevia * need for an emergency delivery (fetal heart rate abnormalities at admission) * contra-indication for vaginal delivery * patient under temporary guardianship, guardianship or judicial protection * patient included in another study which could interfere with the results of this study
quadriceps strengthening acl reconstruction

Conditions: ACL Tear

Summary: the purpose of this study is to investigate the effects of quadriceps focused interventions on knee function and biomechanics in adolescent patients with anterior cruciate ligament reconstruction (aclr)


Eligibility criteria:
inclusion criteria: * no history of knee injury/surgery of the contralateral limb exclusion criteria: * (1) bilateral knee injuries * (2) prior knee ligament injury and/or surgery * (3) multiple ligament injuries and/or ruptures * (4) conditions in which nmes and bfr are contraindicated
a study of flurbiprofen 8.75 mg lozenge in patient with pharyngitis

Conditions: Pharyngitis

Summary: the purposes of this study is to demonstrate the analgesic efficacy of flurbiprofen 8.75 mg lozenge compared to its vehicle lozenge and to demonstrate the safety of the flurbiprofen lozenge throughout the course of treating sore throat due to acute pharyngitis.


Eligibility criteria:
inclusion criteria: 1. the patient has a complaint of sore throat. 2. if the patient is a female of childbearing potential, she has been using effective contraception since the last date of menses and is not breast-feeding or lactating. 3. if the patient is a female of childbearing potential, the patient must have a negative urine pregnancy. 4. the patient has provided written informed consent prior to any study-related procedures. exclusion criteria: 1. the patient has a history of an upper gastrointestinal ulcer within the past 60 days, is currently experiencing clinically significant upper gastrointestinal complaints, or is currently taking medication regularly (≥ three times in the previous week). 2. the patient has a history of any hepatic disease or renal dysfunction. 3. the patient has a history of chronic analgesic use (≥ three times per week over the prior four weeks). (patients on low-dose aspirin therapy may be allowed in the study per investigator's clinical decision.)
a pilot randomized trial of pain neuroscience education in the rehabilitation after arthroscopic rotator cuff repair

Conditions: Rotator Cuff Injuries

Summary: the aim of this study was to evaluate the effects of a 8-week pain neuroscience education programme compared to a biomedical education programme on the rehabilitation of patients who undergo arthroscopic rotator cuff repair. outcome measures included pain intensity, patients' attitudes and beliefs about pain, disability and quality of life.

this was a single-blinded, randomized parallel study. twenty- nine patients who undergo arthroscopic rotator cuff repair took part in a multimodal physiotherapy programme and were allocated to two groups. patients in the experimental group - pne (n= 16) received multimodal physiotherapy along with pain neuroscience education, and the control group- pme (n=13) received multimodal physiotherapy along with biomedical education. the multimodal treatment included 1-hour sessions 3 times per week for 8 weeks (24 sessions). in addition, the education component (pne, pme) consisted of 4 education sessions of 30 minutes duration, on a one-to-one basis, once per week at the start of the programme. physiotherapists involved in the delivery of the interventions were previously trained on both, the theoretical and practical aspects related to the protocols of multimodal physiotherapy and specially on the education component. outcome measures included pain intensity (pain intensity numerical rating score), catastrophizing, kinesiophobia, disability and quality of life.

Eligibility criteria:
inclusion criteria: * people aged 30 to 59 years with shoulder pain for more than three months, with torn rotator cuff repaired by arthroscopy. exclusion criteria: * subjects unable to understand, read or speak spanish, or participated in a programme for psychological management of chronic pain, or presented with generalised pain.
verification of the efficacy and safety of the barostim neo system in the treatment of drug resistant hypertension

Conditions: High Blood Pressure

Summary: to assess the long-term safety and efficacy of the barostim neo system in trial (nct01471834) participants.

the neo non-randomized hypertension study is a non-randomized, open-label, verification study in participants diagnosed with drug resistant hypertension, defined as medical treatment failure for hypertension defined as office cuff systolic blood pressure (sbp) ≥ 140 mmhg despite being prescribed to at least three antihypertensive medications, including a diuretic, in accordance with the aha guidelines. participants should remain on their prescribed anti-hypertensive medications and same dosing schedule for the duration of the study unless investigators determine medically necessary changes are needed. additionally, every effort should be made to maintain adequate rate control for subjects with atrial fibrillation throughout the duration of the study. all (canadian) participants are now in long term follow-up and are required to have at least one annual visit. parameters assessed during long-term follow-up visits: * physical assessment * office cuff blood pressure * subject medications * serious adverse events

Eligibility criteria:
inclusion criteria: * actively participating in the neo non-randomized hypertension study. * have signed a revised approved informed consent form for continued participation in this study. exclusion criteria: * treating physician decision that the subject should not continue with therapy.
controlled trial on effect of montelukast treatment in children with obstructive sleep apnea syndrome

Conditions: Sleep Apnea

Summary: oral therapy with montelukast may lead to improved polysomnographic findings in children with mild to moderate osas with and without allergic rhinitis who a priori require t\&a for osas. - a significant proportion of the children with osas treated with montelukast will show reduced severity of osas, and this will obviate the need for surgical t\&a.

primary specific aim. to conduct a randomized double blind 16-week trial comparing the effect on polysomnographic measures of the administration of once a day oral montelukast therapy vs. placebo in children with osas. secondary specific aim. for all children with the original ahi at diagnosis of \>2 hrtst, we expect improvements in the severity of sleep apnea to occur following treatment with montelukast. therefore, we will examine the overall reduction in ahi and also how many of these children have ahi\< 2 after the 16-week treatment. in other words, the percentage of children converting from needing t\&a surgery before treatment with montelukast to not needing surgery after treatment will be examined.

Eligibility criteria:
inclusion criteria: * symptomatic snoring children \> 2 years of age and \ 2/hrtst (hour total sleep time), and in whom t\&a is therefore contemplated. also among these, we will include children referred for evaluation for snoring who have a history of allergic rhinitis. exclusion criteria: * hypersensitivity to montelukast * immunodeficiency or immunosuppressant therapy * craniofacial, neuromuscular, syndromic or defined genetic abnormalities * acute upper respiratory tract infection * systemic corticosteroid therapy or antibiotic therapy in the 2 weeks previous to the study * children who already had adenotonsillectomy. in addition, children chronically receiving oral antihistamine preparations or nasal decongestants will be required to continue using these medications throughout the duration of the study. patients receiving immunotherapy will continue on the same regimen without escalation of dose and frequency throughout the duration of the study. in addition, patients with severe osa who in the opinion of their treating physicians require early surgical intervention for their osa will be excluded from eligibility to the study.
diagnostic criteria for septic arthritis

Conditions: Septic Arthritis

Summary: septic arthritis (sa) is a rare but highly disabling disease. the ideal diagnosis criteria is not well established. there is an urgent need to establish golden standard for diagnosis.

septic arthritis (sa) is a rare but highly disabling disease. epidemiologic studies have documented an incidence of 0.9-1.3 per 100,000 \[1, 2\]. the treatment is challenging and the ideal diagnosis criteria is not well established. the specific tactics employed by relevant researches varied widely \[3-6\]. patients with recurrent sepsis may require arthrodesis or amputation, which would result in severe functional loss \[2\]. therefore, there is an urgent need to establish golden standard for diagnosis.

Eligibility criteria:
inclusion criteria: * admission to orthopaedics * complete data exclusion criteria: * accompanied with fracture * accompanied with other infections * accompanied with immune system diseases

Keywords: septic arthritis diagnostic criteria